Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ALXN1720

Phase 1Small molecule

ALXN1720 is one of 28 small molecule programs targeting Proteinuria. It is currently in Phase 1.

1

Indications

2

Total Trials

0

Active Trials

27

Competitors

Pipeline

Status by Indication[3][1]

Indication

ProteinuriaActive, not recruiting

ProteinuriaPhase 1

Active, not recruiting

Competition

Competitive Landscape

47 competitors in Proteinuria

#DrugCompanyPhaseTrials

Farxiga

Rocaltrol

Alnylam Pharmaceuticals

Zemplar

Filspari

TTravere Therapeutics, Inc.

Trental

VValidus Pharmaceuticals

Midamor

SGLT2 Inhibitor

Rituxan

Acei/arb

Robitussin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Intravenous1 trial

Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy Subjects

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT04920370·97 enrolled

Proteinuria1 trial

Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT05314231·13 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ALXN1720. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ALXN1720 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ALXN1720. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AstraZeneca

Related News